HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Faculty of Pharmaceutical Sciences >
Peer-reviewed Journal Articles, etc >

A peptide derived from adaptor protein STAP-2 inhibits tumor progression by downregulating epidermal growth factor receptor signaling

This item is licensed under:Creative Commons Attribution 4.0 International

Files in This Item:
A peptide derived from adaptor protein STAP-2 inhibits tumor progression by downregulating epidermal growth factor receptor signaling - PIIS002192582201167X.pdf814.39 kBPDFView/Open
Please use this identifier to cite or link to this item:http://hdl.handle.net/2115/87706

Title: A peptide derived from adaptor protein STAP-2 inhibits tumor progression by downregulating epidermal growth factor receptor signaling
Authors: Maemoto, Taiga Browse this author
Kitai, Yuichi Browse this author →KAKEN DB
Takahashi, Runa Browse this author
Shoji, Haruka Browse this author
Yamada, Shunsuke Browse this author
Takei, Shiho Browse this author
Ito, Daiki Browse this author
Muromoto, Ryuta Browse this author →KAKEN DB
Kashiwakura, Jun-ichi Browse this author →KAKEN DB
Handa, Haruka Browse this author
Hashimoto, Ari Browse this author →KAKEN DB
Hashimoto, Shigeru Browse this author →KAKEN DB
Ose, Toyoyuki Browse this author →KAKEN DB
Oritani, Kenji Browse this author →KAKEN DB
Matsuda, Tadashi Browse this author →KAKEN DB
Keywords: antitumor peptide
prostate cancer
STAT3
EGFR
adaptor protein
Issue Date: 19-Nov-2022
Publisher: American Society for Biochemistry and Molecular Biology
Journal Title: Journal of Biological Chemistry
Volume: 299
Issue: 1
Start Page: 102724
Publisher DOI: 10.1016/j.jbc.2022.102724
Abstract: Signal-transducing adaptor family member-2 (STAP-2) is an adaptor protein that regulates various intracellular signals. We previously demonstrated that STAP-2 binds to epidermal growth factor receptor (EGFR) and facilitates its stability and activation of EGFR signaling in prostate cancer cells. Inhibition of this interaction may be a promising direction for cancer treatment. Here, we found that 2D5 peptide, a STAP-2–derived peptide, blocked STAP-2–EGFR interactions and suppressed EGFR-mediated proliferation in several cancer cell lines. 2D5 peptide inhibited tumor growth of human prostate cancer cell line DU145 and human lung cancer cell line A549 in murine xenograft models. Additionally, we determined that EGFR signaling and its stability were decreased by 2D5 peptide treatment during EGF stimulation. In conclusion, our study shows that 2D5 peptide is a novel anticancer peptide that inhibits STAP-2–mediated activation of EGFR signaling and suppresses prostate and lung cancer progression.
Rights: https://creativecommons.org/licenses/by/4.0/
Type: article
URI: http://hdl.handle.net/2115/87706
Appears in Collections:薬学研究院 (Faculty of Pharmaceutical Sciences) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 松田 正

Export metadata:

OAI-PMH ( junii2 , jpcoar_1.0 )

MathJax is now OFF:


 

 - Hokkaido University